Atlas Trials

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Clinical trial NCT02066038 · UNKNOWN

Trial details

NCT number
NCT02066038
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lung, Carcinoma
Start date
2014-01-01
Primary completion
2015-04-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.